Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections

US8541434B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Southern Research Institute · US

Inventors

• Cecil D. Kwong · Decatur, US
• F. George Njoroge · Hackettstown, US
• Subramaniam Ananthan · Birmingham, US
• Ashok Arasappan · Bound Brook, US
• Frank Bennett · Piscataway, US
• Jeremy Clark · Birmingham, US
• Anita T. Fowler · Irondale, US
• Feng Geng · Hamburg, DE
• Hollis S. Kezar, III · Hoover, US
• Joseph A. Maddry · Birmingham, US
• John J. Piwinski · Lebanon, US
• Robert C. Reynolds · Birmingham, US
• Abhijit Roychowdhury · Birmingham, US
• John A. Secrist, III · Birmingham, US
• Neng-Yang Shih · Lexington, US

Key dates

• Filing date: Aug 19, 2009
• Grant date: Sep 24, 2013
• Expiry date: Aug 23, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I):and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and pro-drugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.